APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lung Cancer Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Lung Cancer Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025181 pages

Choose your research edition.

Industry ResearchLung Cancer Treatment Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Cancer Treatment Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Lung Cancer Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Cancer Treatment Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Cancer Treatment Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Lung Cancer Treatment Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Lung Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lung Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lung Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Lung Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Lung Cancer Treatment Drugs include Sanofi-Aventis, Roche, Eli Lilly and Company, Pfizer, GlaxoSmithKline and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lung Cancer Treatment Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lung Cancer Treatment Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lung Cancer Treatment Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lung Cancer Treatment Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Lung Cancer Treatment Drugs Segment by Company

Sanofi-Aventis

Roche

Eli Lilly and Company

Pfizer

GlaxoSmithKline

AstraZeneca

Lung Cancer Treatment Drugs Segment by Type

Chemotherapy

Pipeline Drugs

Targeted Therapies

Lung Cancer Treatment Drugs Segment by Application

Diagnostic Centers

Hospitals

Research Institutes

Others

Lung Cancer Treatment Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lung Cancer Treatment Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Lung Cancer Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Lung Cancer Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Lung Cancer Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Lung Cancer Treatment Drugs Industry Trends Table 2. Lung Cancer Treatment Drugs Industry Drivers Table 3. Lung Cancer Treatment Drugs Industry Opportunities and Challenges Table 4. Lung Cancer Treatment Drugs Industry Restraints Table 5. Global Lung Cancer Treatment Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Lung Cancer Treatment Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Lung Cancer Treatment Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Lung Cancer Treatment Drugs Sales Market Share by Manufacturers Table 9. Global Lung Cancer Treatment Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Lung Cancer Treatment Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Lung Cancer Treatment Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Lung Cancer Treatment Drugs Manufacturers, Product Type & Application Table 13. Global Lung Cancer Treatment Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Lung Cancer Treatment Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Chemotherapy Table 17. Major Manufacturers of Pipeline Drugs Table 18. Major Manufacturers of Targeted Therapies Table 19. Global Lung Cancer Treatment Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Lung Cancer Treatment Drugs Sales by Type (2021-2026) & (K Units) Table 21. Global Lung Cancer Treatment Drugs Sales by Type (2027-2032) & (K Units) Table 22. Global Lung Cancer Treatment Drugs Sales Market Share by Type (2021-2026) Table 23. Global Lung Cancer Treatment Drugs Sales Market Share by Type (2027-2032) Table 24. Global Lung Cancer Treatment Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Lung Cancer Treatment Drugs Revenue by Type (2021-2026) & (K Units) Table 26. Global Lung Cancer Treatment Drugs Revenue by Type (2027-2032) & (K Units) Table 27. Global Lung Cancer Treatment Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Lung Cancer Treatment Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Diagnostic Centers Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Research Institutes Table 32. Major Manufacturers of Others Table 33. Global Lung Cancer Treatment Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Lung Cancer Treatment Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Lung Cancer Treatment Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Lung Cancer Treatment Drugs Sales Market Share by Application (2021-2026) Table 37. Global Lung Cancer Treatment Drugs Sales Market Share by Application (2027-2032) Table 38. Global Lung Cancer Treatment Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Lung Cancer Treatment Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Lung Cancer Treatment Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Lung Cancer Treatment Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Lung Cancer Treatment Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Lung Cancer Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Lung Cancer Treatment Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Lung Cancer Treatment Drugs Sales Market Share by Region (2021-2026) Table 46. Global Lung Cancer Treatment Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Lung Cancer Treatment Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Lung Cancer Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Lung Cancer Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Lung Cancer Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Lung Cancer Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Lung Cancer Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Lung Cancer Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Lung Cancer Treatment Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Lung Cancer Treatment Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Lung Cancer Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Lung Cancer Treatment Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Lung Cancer Treatment Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Lung Cancer Treatment Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Lung Cancer Treatment Drugs Revenue Market Share by Region (2027-2032) Table 65. Sanofi-Aventis Company Information Table 66. Sanofi-Aventis Business Overview Table 67. Sanofi-Aventis Lung Cancer Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sanofi-Aventis Lung Cancer Treatment Drugs Product Portfolio Table 69. Sanofi-Aventis Recent Development Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Lung Cancer Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Roche Lung Cancer Treatment Drugs Product Portfolio Table 74. Roche Recent Development Table 75. Eli Lilly and Company Company Information Table 76. Eli Lilly and Company Business Overview Table 77. Eli Lilly and Company Lung Cancer Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Eli Lilly and Company Lung Cancer Treatment Drugs Product Portfolio Table 79. Eli Lilly and Company Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Lung Cancer Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer Lung Cancer Treatment Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. GlaxoSmithKline Company Information Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Lung Cancer Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline Lung Cancer Treatment Drugs Product Portfolio Table 89. GlaxoSmithKline Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca Lung Cancer Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. AstraZeneca Lung Cancer Treatment Drugs Product Portfolio Table 94. AstraZeneca Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Lung Cancer Treatment Drugs Distributors List Table 98. Lung Cancer Treatment Drugs Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Lung Cancer Treatment Drugs Product Image Figure 2. Global Lung Cancer Treatment Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Cancer Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Lung Cancer Treatment Drugs Sales (2021-2032) & (K Units) Figure 5. Global Lung Cancer Treatment Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Lung Cancer Treatment Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Chemotherapy Image Figure 9. Pipeline Drugs Image Figure 10. Targeted Therapies Image Figure 11. Global Lung Cancer Treatment Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Lung Cancer Treatment Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Lung Cancer Treatment Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Lung Cancer Treatment Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Lung Cancer Treatment Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Lung Cancer Treatment Drugs Revenue Market Share by Type (2021-2032) Figure 17. Diagnostic Centers Image Figure 18. Hospitals Image Figure 19. Research Institutes Image Figure 20. Others Image Figure 21. Global Lung Cancer Treatment Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Lung Cancer Treatment Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Lung Cancer Treatment Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Lung Cancer Treatment Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Lung Cancer Treatment Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Lung Cancer Treatment Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Lung Cancer Treatment Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Lung Cancer Treatment Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Lung Cancer Treatment Drugs Sales Market Share by Country (2021-2032) Figure 41. China Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Lung Cancer Treatment Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Lung Cancer Treatment Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Lung Cancer Treatment Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Lung Cancer Treatment Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Lung Cancer Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Lung Cancer Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Lung Cancer Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Lung Cancer Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Lung Cancer Treatment Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Lung Cancer Treatment Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Pipeline Drugs
  • Targeted Therapies
Applications
  • Diagnostic Centers
  • Hospitals
  • Research Institutes
  • Others
Companies covered
  • Sanofi-Aventis
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lung Cancer Treatment Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lung Cancer Treatment Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Lung Cancer Treatment Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Lung Cancer Treatment Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Lung Cancer Treatment Drugs Market Dynamics
  1. 2.1 Lung Cancer Treatment Drugs Industry Trends
  2. 2.2 Lung Cancer Treatment Drugs Industry Drivers
  3. 2.3 Lung Cancer Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 Lung Cancer Treatment Drugs Industry Restraints
3 Lung Cancer Treatment Drugs Market by Manufacturers
  1. 3.1 Global Lung Cancer Treatment Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Lung Cancer Treatment Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Lung Cancer Treatment Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Lung Cancer Treatment Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Lung Cancer Treatment Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Lung Cancer Treatment Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Lung Cancer Treatment Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Lung Cancer Treatment Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Lung Cancer Treatment Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Lung Cancer Treatment Drugs Tier 1, Tier 2, and Tier 3
4 Lung Cancer Treatment Drugs Market by Type
  1. 4.1 Lung Cancer Treatment Drugs Type Introduction
  2. 4.1.1 Chemotherapy
  3. 4.1.2 Pipeline Drugs
  4. 4.1.3 Targeted Therapies
  5. 4.2 Global Lung Cancer Treatment Drugs Sales by Type
  6. 4.2.1 Global Lung Cancer Treatment Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Lung Cancer Treatment Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Lung Cancer Treatment Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Lung Cancer Treatment Drugs Revenue by Type
  10. 4.3.1 Global Lung Cancer Treatment Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Lung Cancer Treatment Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Lung Cancer Treatment Drugs Revenue Market Share by Type (2021-2032)
5 Lung Cancer Treatment Drugs Market by Application
  1. 5.1 Lung Cancer Treatment Drugs Application Introduction
  2. 5.1.1 Diagnostic Centers
  3. 5.1.2 Hospitals
  4. 5.1.3 Research Institutes
  5. 5.1.4 Others
  6. 5.2 Global Lung Cancer Treatment Drugs Sales by Application
  7. 5.2.1 Global Lung Cancer Treatment Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Lung Cancer Treatment Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Lung Cancer Treatment Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Lung Cancer Treatment Drugs Revenue by Application
  11. 5.3.1 Global Lung Cancer Treatment Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Lung Cancer Treatment Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Lung Cancer Treatment Drugs Revenue Market Share by Application (2021-2032)
6 Global Lung Cancer Treatment Drugs Sales by Region
  1. 6.1 Global Lung Cancer Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lung Cancer Treatment Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Lung Cancer Treatment Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Lung Cancer Treatment Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Lung Cancer Treatment Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Lung Cancer Treatment Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Lung Cancer Treatment Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Lung Cancer Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Lung Cancer Treatment Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Lung Cancer Treatment Drugs Revenue by Region
  1. 7.1 Global Lung Cancer Treatment Drugs Revenue by Region
  2. 7.1.1 Global Lung Cancer Treatment Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Lung Cancer Treatment Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Lung Cancer Treatment Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Lung Cancer Treatment Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Lung Cancer Treatment Drugs Revenue (2021-2032)
  8. 7.2.2 North America Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Lung Cancer Treatment Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Lung Cancer Treatment Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Lung Cancer Treatment Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Lung Cancer Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi-Aventis
  2. 8.1.1 Sanofi-Aventis Company Information
  3. 8.1.2 Sanofi-Aventis Business Overview
  4. 8.1.3 Sanofi-Aventis Lung Cancer Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi-Aventis Lung Cancer Treatment Drugs Product Portfolio
  6. 8.1.5 Sanofi-Aventis Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Lung Cancer Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Lung Cancer Treatment Drugs Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company Lung Cancer Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company Lung Cancer Treatment Drugs Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Lung Cancer Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Lung Cancer Treatment Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Lung Cancer Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Lung Cancer Treatment Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Lung Cancer Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Lung Cancer Treatment Drugs Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lung Cancer Treatment Drugs Value Chain Analysis
  2. 9.1.1 Lung Cancer Treatment Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lung Cancer Treatment Drugs Production Mode & Process
  6. 9.2 Lung Cancer Treatment Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lung Cancer Treatment Drugs Distributors
  9. 9.2.3 Lung Cancer Treatment Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst